Picture of automobile manufacturing plant

Driving innovations in manufacturing: Open Access research from DMEM

Strathprints makes available Open Access scholarly outputs by Strathclyde's Department of Design, Manufacture & Engineering Management (DMEM).

Centred on the vision of 'Delivering Total Engineering', DMEM is a centre for excellence in the processes, systems and technologies needed to support and enable engineering from concept to remanufacture. From user-centred design to sustainable design, from manufacturing operations to remanufacturing, from advanced materials research to systems engineering.

Explore Open Access research by DMEM...

Essential role for proteinase-activated receptor-2 in arthritis

Ferrell, W.R. and Lockhart, J.C. and Kelso, E.B. and Dunning, L. and Plevin, R.J. and Meek, S.E. and Smith, A.J. and Hunter, G.D. and McLean, J.S. and McGarry, F. and Ramage, R. and Jiang, L. and Kanke, T. and Kawagoe, J. (2003) Essential role for proteinase-activated receptor-2 in arthritis. Journal of Clinical Investigation, 111 (1). pp. 35-41. ISSN 0021-9738

[img]
Preview
PDF (jci.pdf)
jci.pdf - Accepted Author Manuscript

Download (1MB) | Preview

Abstract

Using physiological, pharmacological, and gene disruption approaches, we demonstrate that proteinase-activated receptor-2 (PAR-2) plays a pivotal role in mediating chronic inflammation. Using an adjuvant monoarthritis model of chronic inflammation, joint swelling was substantially inhibited in PAR-2-deficient mice, being reduced by more than fourfold compared with wild-type mice, with virtually no histological evidence of joint damage. Mice heterozygous for PAR-2 gene disruption showed an intermediate phenotype. PAR-2 expression, normally limited to endothelial cells in small arterioles, was substantially upregulated 2 weeks after induction of inflammation, both in synovium and in other periarticular tissues. PAR-2 agonists showed potent proinflammatory effects as intra-articular injection of ASKH95, a novel synthetic PAR-2 agonist, induced prolonged joint swelling and synovial hyperemia. Given the absence of the chronic inflammatory response in the PAR-2-deficient mice, our findings demonstrate a key role for PAR-2 in mediating chronic inflammation, thereby identifying a novel and important therapeutic target for the management of chronic inflammatory diseases such as rheumatoid arthritis.